Characterization of beta-adrenergic receptors in DiFi and HT-29 cells

Peter W. Abel, W. Zeng, D. M. Wildrick, M. C. Makoid, B. M. Boman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The beta-adrenergic receptors present in two human colorectal adenocarcinoma cell lines were characterized by measuring specific binding of [125I]-cyanopindolol (CYP). Whole. cultured, DiFi (derived from a familial adenomatous polyposis [FAP] patient) and HT-29 cells were used in radioligand binding assays. Scatchard analysis of specific 125I-CYP binding gave K(DS)of 38.6 ± 5.7 pM in DiFi cells and 54 ± 9.1 pM in HT-29 cells. However, binding site density (B(max)) in the DiFi cells was greater than that in HT-29 cell.s. In DiFi cells, the kinetically determined K(D) was similar to that calculated from Scatchard analysis. Studies in DiFi cells of the displacement of specific 125I-CYP binding by nonselective (propranolol), beta1-selective (metoprolol and atenolol), and beta2-selective (ICI 118-551) antagonists revealed only a single class of beta2-adrenergic receptors. This provides the first evidence that colorectal adenocarcinoma cell lines contain beta-adrenergic receptors and shows that only beta2-adrenergic receptors are present in DiFi cells. Mechanisms possibly affecting beta-adrenergic-receptor expression in such cells are discussed in relation to colon carcinogenesis.

Original languageEnglish
Pages (from-to)1655-1658
Number of pages4
JournalAnticancer Research
Volume12
Issue number5
StatePublished - 1992

Fingerprint

HT29 Cells
Receptors, Adrenergic, beta
Adrenergic Receptors
Adenocarcinoma
Cell Line
Radioligand Assay
Adenomatous Polyposis Coli
Metoprolol
Atenolol
Propranolol
Colon
Carcinogenesis
Binding Sites
cyanopindolol

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Abel, P. W., Zeng, W., Wildrick, D. M., Makoid, M. C., & Boman, B. M. (1992). Characterization of beta-adrenergic receptors in DiFi and HT-29 cells. Anticancer Research, 12(5), 1655-1658.

Characterization of beta-adrenergic receptors in DiFi and HT-29 cells. / Abel, Peter W.; Zeng, W.; Wildrick, D. M.; Makoid, M. C.; Boman, B. M.

In: Anticancer Research, Vol. 12, No. 5, 1992, p. 1655-1658.

Research output: Contribution to journalArticle

Abel, PW, Zeng, W, Wildrick, DM, Makoid, MC & Boman, BM 1992, 'Characterization of beta-adrenergic receptors in DiFi and HT-29 cells', Anticancer Research, vol. 12, no. 5, pp. 1655-1658.
Abel PW, Zeng W, Wildrick DM, Makoid MC, Boman BM. Characterization of beta-adrenergic receptors in DiFi and HT-29 cells. Anticancer Research. 1992;12(5):1655-1658.
Abel, Peter W. ; Zeng, W. ; Wildrick, D. M. ; Makoid, M. C. ; Boman, B. M. / Characterization of beta-adrenergic receptors in DiFi and HT-29 cells. In: Anticancer Research. 1992 ; Vol. 12, No. 5. pp. 1655-1658.
@article{aac39d5b6bce43e7a14174b85ff99243,
title = "Characterization of beta-adrenergic receptors in DiFi and HT-29 cells",
abstract = "The beta-adrenergic receptors present in two human colorectal adenocarcinoma cell lines were characterized by measuring specific binding of [125I]-cyanopindolol (CYP). Whole. cultured, DiFi (derived from a familial adenomatous polyposis [FAP] patient) and HT-29 cells were used in radioligand binding assays. Scatchard analysis of specific 125I-CYP binding gave K(DS)of 38.6 ± 5.7 pM in DiFi cells and 54 ± 9.1 pM in HT-29 cells. However, binding site density (B(max)) in the DiFi cells was greater than that in HT-29 cell.s. In DiFi cells, the kinetically determined K(D) was similar to that calculated from Scatchard analysis. Studies in DiFi cells of the displacement of specific 125I-CYP binding by nonselective (propranolol), beta1-selective (metoprolol and atenolol), and beta2-selective (ICI 118-551) antagonists revealed only a single class of beta2-adrenergic receptors. This provides the first evidence that colorectal adenocarcinoma cell lines contain beta-adrenergic receptors and shows that only beta2-adrenergic receptors are present in DiFi cells. Mechanisms possibly affecting beta-adrenergic-receptor expression in such cells are discussed in relation to colon carcinogenesis.",
author = "Abel, {Peter W.} and W. Zeng and Wildrick, {D. M.} and Makoid, {M. C.} and Boman, {B. M.}",
year = "1992",
language = "English",
volume = "12",
pages = "1655--1658",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Characterization of beta-adrenergic receptors in DiFi and HT-29 cells

AU - Abel, Peter W.

AU - Zeng, W.

AU - Wildrick, D. M.

AU - Makoid, M. C.

AU - Boman, B. M.

PY - 1992

Y1 - 1992

N2 - The beta-adrenergic receptors present in two human colorectal adenocarcinoma cell lines were characterized by measuring specific binding of [125I]-cyanopindolol (CYP). Whole. cultured, DiFi (derived from a familial adenomatous polyposis [FAP] patient) and HT-29 cells were used in radioligand binding assays. Scatchard analysis of specific 125I-CYP binding gave K(DS)of 38.6 ± 5.7 pM in DiFi cells and 54 ± 9.1 pM in HT-29 cells. However, binding site density (B(max)) in the DiFi cells was greater than that in HT-29 cell.s. In DiFi cells, the kinetically determined K(D) was similar to that calculated from Scatchard analysis. Studies in DiFi cells of the displacement of specific 125I-CYP binding by nonselective (propranolol), beta1-selective (metoprolol and atenolol), and beta2-selective (ICI 118-551) antagonists revealed only a single class of beta2-adrenergic receptors. This provides the first evidence that colorectal adenocarcinoma cell lines contain beta-adrenergic receptors and shows that only beta2-adrenergic receptors are present in DiFi cells. Mechanisms possibly affecting beta-adrenergic-receptor expression in such cells are discussed in relation to colon carcinogenesis.

AB - The beta-adrenergic receptors present in two human colorectal adenocarcinoma cell lines were characterized by measuring specific binding of [125I]-cyanopindolol (CYP). Whole. cultured, DiFi (derived from a familial adenomatous polyposis [FAP] patient) and HT-29 cells were used in radioligand binding assays. Scatchard analysis of specific 125I-CYP binding gave K(DS)of 38.6 ± 5.7 pM in DiFi cells and 54 ± 9.1 pM in HT-29 cells. However, binding site density (B(max)) in the DiFi cells was greater than that in HT-29 cell.s. In DiFi cells, the kinetically determined K(D) was similar to that calculated from Scatchard analysis. Studies in DiFi cells of the displacement of specific 125I-CYP binding by nonselective (propranolol), beta1-selective (metoprolol and atenolol), and beta2-selective (ICI 118-551) antagonists revealed only a single class of beta2-adrenergic receptors. This provides the first evidence that colorectal adenocarcinoma cell lines contain beta-adrenergic receptors and shows that only beta2-adrenergic receptors are present in DiFi cells. Mechanisms possibly affecting beta-adrenergic-receptor expression in such cells are discussed in relation to colon carcinogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0026498326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026498326&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1655

EP - 1658

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -